Abstract. There is renewed interest in the rich nickel and cobalt deposits of Pulau Gag, an isolated but malarious island off the northwest coast of Irian Jaya. In preparation for an expanded workforce, an environmental assessment of malaria risk was made, focusing upon malaria prevalence in the small indigenous population, and the in vivo sensitivity of Plasmodium falciparum and P. vivax to chloroquine (CQ) and sulfadoxine/pyrimethamine (S/P), the respective first-and second-line drugs for uncomplicated malaria in Indonesia. During April-June 1997, mildly symptomatic or asymptomatic malaria infections were found in 24% of 456 native residents. Infections by P. falciparum accounted for 60% of the cases. Respective day 28 cure rates for CQ (10 mg base/kg on days 0 and 1; 5 mg/kg on day 2) in children and adults were 14% and 55% (P Ͻ 0.005). Type RII and RIII resistance characterized only 5% of the CQ failures. Re-treatment of 36 P. falciparum CQ treatment failures with S/P (25 mg/kg and 1.25 mg/kg, respectively) demonstrated rapid clearance and complete sensitivity during the 28-day follow-up period. More than 97% of the P. vivax malaria cases treated with CQ cleared parasitemia within 48 hr. Three cases of P. vivax malaria recurred between days 21 and 28, but against low drug levels in the blood. The low frequency of RII and RIII P. falciparum resistance to CQ, the complete sensitivity of this species to S/P, and the absence of CQ resistance by P. vivax are in contrast to in vivo and in vitro test results from sites on mainland Irian Jaya.
Prospective ventures seeking to develop promising mineral and petroleum deposits in Indonesia must consider the impact of the local environment upon their operation as well as the impact of their disturbances on the environment. Indonesia's eastern province of Irian Jaya is plagued with the highest levels of malaria in this, the world's fourth most populous, nation. Irian Jaya has been a particular focus of research and control efforts because of widespread, drugresistant Plasmodium falciparum and P. vivax malaria. In vitro resistance by strains of P. falciparum from Irian Jaya has been reported against chloroquine (CQ), amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine (S/P). 1, 2 The frequency of in vivo resistance by P. falciparum to CQ has increased from 53% during 1986-1990 to 71% during 1991-1995, with 56% of these latter cases classified as RII and RIII-type resistance. 3 Low levels of in vivo resistance to S/P were recorded in 1982, 4, 5 but by 1995 high frequencies of in vivo resistance to S/P, and to S/P in combination with CQ, had been reported. 2, 3 Recently, low level RI-type resistance against artemether has been reported from southern Irian Jaya. 6 Plasmodium vivax malaria, which accounts for almost half the clinical cases seen, has demonstrated resistance to CQ treatment at multiple locations in Irian Jaya. [7] [8] [9] [10] This report describes an assessment of malaria that was conducted in preparation for a new mining venture on an island off the northwest coast of Irian Jaya, Indonesia. We sought to learn whether malaria at this location had acquired antimalarial resistance typical of the mainland, or had remained distinct by virtue of isolation and naturally acquired immunity in the resident population. Principal elements of this assessment were 1) the prevalence of malaria by age groups among the native inhabitants and 2) the in vivo sensitivity of P. falciparum and P. vivax malaria from this population to CQ and S/P, the respective first-and second-line treatments for uncomplicated malaria in Indonesia. 3 
SUBJECTS AND METHODS
Study site and subjects. The isolated islands of Gag and Gebe, situated in the Halmahera Sea between the Irian Jaya ''bird's head'' and Halmahera, in the Maluku Islands, have been mined for nickel and cobalt since the mid 1960s. Market demands, new assessments, and improved recovery technologies have rekindled interest in Gag Island as a major mining, processing, and smelting site with a potential workforce of 10,000. Gag Island, located at 00Њ26'S, 29Њ54'E within the administrative province of Irian Jaya, acquired a permanent population as a result of early mining activities. These residents originated from Maluku and Sulawesi and established the shoreline village of Gambir (113 houses) on a sheltered northeastern bay surrounded by sago swamp and forest. Subsistence level fishing, gardening, and some copra and cacao production support a resident population of approximately 500. Land and soil conditions suitable for agriculture exist only along the northern and eastern shores and comprise less than one-tenth of the island's area of 56 km 2 . At the time of our survey, there were approximately 200 non-indigenous or offshore mining personnel temporarily resident in Camp 1, adjacent to Gambir.
Malaria screening and in vivo testing. An invitation was made in April 1997 for all residents and offshore mining personnel present on Pulau Gag to undergo screening for malaria infection. Thick and thin blood smears were stained with Giemsa and screened by high power (1,000ϫ, oil-immersion) microscopy. Spleens of native island residents were palpated and cases of enlargement were recorded. Malaria screenings were conducted over several nights, between 8:00 PM and 11:00 PM to permit simultaneous microscopic screening of fresh blood for microfilarial infections. Individuals with at least one asexual stage parasite per 200 white blood cells in the thick smear preparation were enrolled as informed, consenting volunteers if they had not consumed an antimalarial in the previous week, did not have a chronic illness, were able to swallow CQ tablets, and in the case of children with parental consent, were at least five years old. A standard dosage/weight treatment regimen of CQ (10 mg/ kg on days 0 and 1, and 5 mg/kg on day 2) was administered with food. Blood films were made on days 0, 2, 4, 7, 11, 14, 18, 21, and 28, or on any day that symptoms warranted checking, and 300 thick film fields were screened for parasites. On days 0, 2, and at the time of a switch to S/P treatment because of unremitting or recurrent parasitemia within the 28-day test period, 100 ml of whole blood was blotted onto Whatman (Maidstone, United Kingdom) No.1 filter paper for determination of CQ levels. Chloroquine and its major active metabolite desethylchloroquine (DCQ) were measured from dried filter paper blots according to published methods. 11 Drug levels above the estimated minimum effective concentration (MEC) of 200 ng of CQ plus DCQ/ml of whole blood for P. falciparum at the time of recurrence or reinfection and above the estimated MEC of 100 ng of CQ plus DCQ/ml of whole blood for P. vivax at the time of recurrence/relapse/reinfection were used to confirm resistance in cases of therapeutic failure. 10, 12, 13 In accordance with Indonesian National Health Policy, individuals with unremitting or recurrent parasitemias were provided a single curative dose of S/P (25 mg of sulfadoxine/kg and 1.25 mg of pyrimethamine/kg) with food, and were monitored as described for CQ follow-up. Ethical review and approval. This work was conducted in accordance with U.S. Navy and Republic of Indonesia regulations governing the protection of human subjects in medical research. American and Indonesian committees for the protection of human subjects reviewed and approved the procedures followed in this research (NAMRU-2 Research Protocol #94-24).
RESULTS
Malaria prevalence and in vivo test enrollment. Malaria prevalence in 456 residents of Gambir was 24.3% (111 of 456) with P. falciparum infections slightly dominant (Table  1) . Malaria was significantly more prevalent among children 2-15 years old than among adults (P. falciparum: 32 of 188 versus 16 of 209; P Ͻ 0.0001; P. vivax: 31 of 188 versus 8 of 209; P Ͻ 0.0001). Seventy-four of the 111 malaria infections found by screening were eligible for enrollment and provided informed consent for participation in the 28-day in vivo test of CQ sensitivity/resistance. Available offshore mine employees were screened for malaria and filaria infection. Screening point prevalence of malaria in this subpopulation was 5.4% (2 P. falciparum and 4 P. vivax/112). Three of these P. vivax cases were enrolled into the 28-day in vivo test for CQ resistance.
Pediatric (n ϭ 42) and adult (n ϭ 35) infections were either asymptomatic (children, 36% versus adults, 29%; P ϭ 0.66) or mildly symptomatic (headache, malaise, nausea, arthralgia, myalgia, fever, upper respiratory infection symptoms) at enrollment. Fever characterized 17% and 14% of the respective pediatric and adult cases. Symptoms of only upper respiratory infection were present in 24% of the children and 6% of the adults. Table 2 presents results of 28-day in vivo tests for CQ sensitivity/resistance conducted with 
Comparative proportion of native children and adults with recurrent parasitemia following chloroquine therapy for uncomplicated Plasmodium falciparum malaria on Pulau Gag, northwest Irian Jaya, Indonesia, April-June 1997. Children (n ϭ 23, mean Ϯ SD age ϭ 7.9 Ϯ 2.3 years); adults (n ϭ 21, mean Ϯ SD age ϭ 26.6 Ϯ 10.5 years). FIGURE 2. Comparative peak (day 2) levels of chloroquine (CQ) in whole blood of children and adults treated for uncomplicated malaria on Gag Island, northwest Irian Jaya, Indonesia, April-June 1997. DCQ ϭ desethychloroquine. *Day 2 whole blood levels of CQ plus DCQ are given as means with 95% confidence intervals. 44 cases of P. falciparum and 26 cases of P. vivax malaria. Of the 66 subjects that provided full post-treatment followup data, there were 40 P. falciparum infections, 22 P. vivax infections, and four mixed infections. Malaria cases not enrolled in this study received standard CQ treatment and follow-up through local health care providers.
Chloroquine in vivo test results. Within the first 48 hr of CQ treatment, 41 (87%) of 47 P. falciparum malaria cases demonstrated a 75-100% decrease in parasitemia. Four of the six exceptions showed no decrease, two decreased by only 50%, and one increased. All of these began as low parasitemias (range ϭ 80-1,240/l). The frequency and time scale for clearance of 47 P. falciparum parasitemias was 63.8% (30 of 47) by day 2 and 95.7% (45 of 47) by day 4. Two cases remained parasitemic through day 4 and four cases, which cleared by day 4, but demonstrated recurrent parasitemias on day 7, were provided S/P therapy. Chloroquine blood levels in two of these four cases were above the 200 ng/ml MEC used for delineating CQ resistance by this species. The other two had abnormally low drug levels, suggestive of inadequate absorption. Among the 22 other P. falciparum malaria cases in which parasites reappeared on test days 11-28, only one case (day 18 recrudescence) demonstrated drug levels above the MEC. The World Health Organization (WHO) classification of P. falciparum responses to CQ based upon parasitologic criteria alone is provided in Table 3 . Figure 1 compares the cumulative proportion of therapeutic failures by in vivo test week for the 23 children (mean Ϯ SD age ϭ 7.9 Ϯ 2.3 years) and 21 adults (mean Ϯ SD age ϭ 26.6 Ϯ 10.5 years) tested. This plot shows that children were significantly more prone to late CQ therapeutic failures than adults. Consistent with these results, the results in Figure 2 demonstrate that the mean day 2 drug levels of CQ plus DCQ in children were significantly lower than those of adults. This was evident for all malaria cases (mean ϭ 567 versus 729; P ϭ 0.003) and for P. falciparum cases only (mean ϭ 511 versus 675; P ϭ 0.02).
Plasmodium vivax responded more rapidly to CQ than P. falciparum. More than 97% (37 of 38) cases cleared within the first 48 hr of treatment (day 2), and the single case that cleared by day 4 showed a 10-fold decrease in parasitemia within the first 48 hr. Although 38 cases of P. vivax malaria were enrolled and treated, intercurrent infection by P. falciparum and early withdrawal from the study reduced the number of valid assessments to 26 cases. Plasmodium vivax parasitemias recurred between days 21 and 28 in 11.5% (3 of 26) of the cases. However, drug levels were below the MEC of 100 ng of CQ plus DCQ/ml of whole blood used to delineate resistance by this species in all three cases. Since each of these cases demonstrated adequate day 2 levels of drug in their blood (467, 452, and 512 ng/ml), and parasites appeared late in the in vivo test period, we suspect the parasites represent relapses, or distinct secondary infections that were acquired just prior to, or during treatment.
Sulfadoxine/pyrimethamine in vivo test results. According to the national health policy of Indonesia, S/P was given to cases of P. falciparum malaria considered therapeutic failures of CQ (parasites reappeared within 28 days of receiving CQ). There were 46 such cases in the study population surveyed. Geometric mean density of P. falciparum in these cases was 449 asexual stages/ml (95% confidence interval ϭ 302-666) of blood. Response of P. falciparum to S/P was rapid; 82.6% (38 of 46) of the parasitemias cleared within 48 hr of receiving the drug and all 46 parasitemias cleared by day 4. Of the 46 cases given S/P, one case dropped out negative on day 7 and nine others withdrew, also negative, after 14 days of follow-up. Complete follow-up, performed on 36 cases, revealed no patent recurrent parasitemias during the 28-day test.
DISCUSSION
The high prevalence of malaria in the resident population of Gag Island, combined with high spleen rates in children and the relatively light symptoms of disease recorded in all age groups, suggest that malaria is mesoendemic on the island and that transmission is sufficiently intense to promote clinical immunity in even the lower age groups. Chloroquine treatment provided typically rapid clearance of parasites in the majority of patients, but P. falciparum parasites reappeared in 64% of these cases. Despite a low cure rate, mild symptoms characterized only 24% of these failures and less than 5% were of the RII/RIII type. This is in contrast to other sites on mainland Irian Jaya where RII/RIII resistance to CQ occurs in 30-56% of the cases. 2-5,7-10 The complementary effects of host immunity upon the action of antimalarials, which has long been assumed, 14 may account for the different CQ cure rates we observed in adults and children native to Gag Island. This was not apparent in S/P treatments, which demonstrated uniform sensitivity in both age groups. In Myanmar, in vivo tests showed better responses in adults compared with children following either CQ or S/P treatment. These differences were evident by day 7 for CQ, but not until days 14-28 for S/P. 15 A seven-day in vivo study in Irian Jaya showed no distinction between long-and short-term exposure groups treated with CQ, but did show a clear difference in their response to S/P. 2 Whole blood levels of CQ plus DCQ, measured on day 2 of treatment in the Gag Island population, were low relative to other populations surveyed, 10, 12, 13, [16] [17] [18] and reinfections may account for the majority of therapeutic failures seen. Relative to adults, the significantly lower drug levels that we measured in children suggest that poor drug absorption, rather than immature or undeveloped immunity, may account for the higher frequency of therapeutic failures seen in this group. Interestingly, despite generally low CQ blood levels and numerous P. falciparum recurrences, few P. vivax parasitemias appeared during the 28-day test period in either age group, and none of these cases did so against normally suppressive drug levels.
The low frequency of RII and RIII P. falciparum resistance to CQ, the complete sensitivity of this species to S/P, and the absence of CQ resistance by P. vivax collectively provide evidence of minimal importation or cross-over of the mainland malaria into the resident population. The ethnic character of the Gag Island population, and their family ties outside the island, suggest that the population of circulating malaria may derive primarily from Maluku, rather than from Irian Jaya origins. We had anticipated moderate to high levels of CQ and S/P resistance as a result of four contributing mechanisms: 1) the presence of Anopheles farauti, an efficient malaria vector found at high density in the vicinity of both mining camp and native village; 2) the proximity of the native village to the mining camp, facilitating transfer of resistant parasite strains; 3) the importation of resistant strains onto the island as asymptomatic infections in clinically-immune carriers from mainland Irian Jaya, Papua New Guinea, and Biak and Serui Islands; and 4) the gradual inducement of resistance in the island's malaria by decades of routine and haphazard prophylaxis in a large workforce. Why comparable levels of CQ and S/P resistance have not developed during more than 30 years of intensive nickel mining is unclear. Records from 1975 show that while malaria prevalence was high among native residents of Gambir (38%), none of the offshore workers then living in Camp 1 were infected, and that a weekly program of CQ prophylaxis was in effect for the miners. 19 Our current findings, 22 years later, are surprisingly similar (natives ϭ 24.3%, offshore ϭ 5.4%) revealing that 45% (51 of 112) of the offshore workers were from towns in Irian Jaya, and that most of the workforce used either weekly CQ prophylaxis (55 of 112) or none at all (47 of 112).
We conclude that S/P has excellent efficacy for treatment of P. falciparum malaria acquired on Gag Island and that P. vivax at this location remains highly sensitive to standard CQ therapy. Low levels of RII and RIII CQ resistance by P. falciparum were detected. The majority of CQ failures were RI-type therapeutic failures, not clinical failures, and presumably result from low levels of drug absorption, a factor that was most pronounced in children. These collective lines of evidence suggest that the character of malaria occurring on Gag Island is distinct from that of the Irian Jaya mainland, and may therefore be more amenable to treatment and control. According to WHO guidelines, the clinical failure rate even among children for CQ treatment is too low to justify its replacement by S/P. 20 However, health providers should weigh the cost/benefit of replacing CQ with S/P as the first-line treatment for uncomplicated symptomatic P. falciparum malaria acquired on Gag Island, and the potential for eliminating malaria entirely from the island. Important consideration must be given to the lack of protective malaria immunity in small children and nonindigenous workers, the possibility of Steven's-Johnson syndrome in a small portion of individuals who receive S/P, and to the loss of naturallyacquired immunity in the native population as a result of effective malaria prevention and control strategies that could be implemented by the mining company. 
